Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 238

1.

Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.

Molina I, Falcó V, Crespo M, Riera C, Ribera E, Curran A, Carrio J, Diaz M, Villar del Saz S, Fisa R, López-Chejade P, Ocaña I, Pahissa A.

J Antimicrob Chemother. 2007 Oct;60(4):837-42. Epub 2007 Aug 7.

PMID:
17684055
2.

Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.

López-Vélez R, Videla S, Márquez M, Boix V, Jiménez-Mejías ME, Górgolas M, Arribas JR, Salas A, Laguna F, Sust M, Cañavate C, Alvar J; Spanish HIV-Leishmania Study Group.

J Antimicrob Chemother. 2004 Mar;53(3):540-3. Epub 2004 Jan 22.

PMID:
14739148
3.

Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients.

Ribera E, Ocaña I, de Otero J, Cortes E, Gasser I, Pahissa A.

Am J Med. 1996 May;100(5):496-501.

PMID:
8644760
4.

Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome.

ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN.

Clin Infect Dis. 2008 Jun 1;46(11):1702-9. doi: 10.1086/587899.

PMID:
18419422
5.

Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.

Lachaud L, Bourgeois N, Plourde M, Leprohon P, Bastien P, Ouellette M.

Clin Infect Dis. 2009 Jan 15;48(2):e16-22. doi: 10.1086/595710.

PMID:
19093811
6.

Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.

Sinha PK, van Griensven J, Pandey K, Kumar N, Verma N, Mahajan R, Kumar P, Kumar R, Das P, Mitra G, Flevaud L, Ferreyra C, Remartinez D, Pece M, Palma PP.

Clin Infect Dis. 2011 Oct;53(7):e91-8. doi: 10.1093/cid/cir521.

PMID:
21890763
7.

[Liposomal amphotericin B in secondary prophylaxis of visceral leishmaniasis in HIV-infected patients: report of five clinical cases].

Montana M, Chochoi N, Monges P, Ravaux I, Faraut F, Gensollen S, Bongrand MC, Timon-David P, Gallais H.

Pathol Biol (Paris). 2004 Mar;52(2):66-75. Review. French.

PMID:
15001234
8.

Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.

Laguna F, López-Vélez R, Pulido F, Salas A, Torre-Cisneros J, Torres E, Medrano FJ, Sanz J, Picó G, Gómez-Rodrigo J, Pasquau J, Alvar J.

AIDS. 1999 Jun 18;13(9):1063-9.

PMID:
10397536
9.

Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome).

Russo R, Nigro LC, Minniti S, Montineri A, Gradoni L, Caldeira L, Davidson RN.

J Infect. 1996 Mar;32(2):133-7.

PMID:
8708370
10.

Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.

Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R.

Clin Infect Dis. 2003 Sep 15;37(6):800-4. Epub 2003 Aug 28.

PMID:
12955641
11.

A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience.

Cascio A, di Martino L, Occorsio P, Giacchino R, Catania S, Gigliotti AR, Aiassa C, Iaria C, Giordano S, Colomba C, Polara VF, Titone L, Gradoni L, Gramiccia M, Antinori S.

J Antimicrob Chemother. 2004 Jul;54(1):217-20. Epub 2004 May 18.

PMID:
15150166
12.

Protective Efficacy of Secondary Prophylaxis Against Visceral Leishmaniasis in Human Immunodeficiency Virus Coinfected Patients Over the Past 10 Years in Eastern India.

Goswami RP, Goswami RP, Basu A, Ray Y, Rahman M, Tripathi SK.

Am J Trop Med Hyg. 2017 Feb 8;96(2):285-291. doi: 10.4269/ajtmh.16-0432. Epub 2016 Nov 22.

PMID:
27879457
13.

[Change in human visceral leishmaniasis treatment in Italy: retrospective study of 630 patients].

Gradoni L, Gramiccia M, Scalone A.

Parassitologia. 2004 Jun;46(1-2):199-201. Review. Italian.

PMID:
15305716
14.

Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy.

Mira JA, Corzo JE, Rivero A, Macias J, De Leon FL, Torre-Cisneros J, Gomez-Mateos J, Jurado R, Pineda JA.

Am J Trop Med Hyg. 2004 Mar;70(3):298-301.

PMID:
15031520
15.

Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study.

Pintado V, Martín-Rabadán P, Rivera ML, Moreno S, Bouza E.

Medicine (Baltimore). 2001 Jan;80(1):54-73.

16.

Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients.

Marques N, Sá R, Coelho F, Oliveira J, Saraiva Da Cunha J, Meliço-Silvestre A.

Scand J Infect Dis. 2008;40(6-7):523-6. doi: 10.1080/00365540701787800.

PMID:
18584541
17.

Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.

Laguna F, Videla S, Jiménez-Mejías ME, Sirera G, Torre-Cisneros J, Ribera E, Prados D, Clotet B, Sust M, López-Vélez R, Alvar J; Spanish HIV-Leishmania Study Group.

J Antimicrob Chemother. 2003 Sep;52(3):464-8. Epub 2003 Jul 29.

PMID:
12888588
18.

[The clinical and evolutional characteristics of visceral leishmaniasis in patients with HIV infection].

Delgado Fernández M, García Ordoñez MA, Martos Pérez F, Reguera Iglesias JM, Jiménez Oñate F, Colmenero Castillo JD.

An Med Interna. 1997 Oct;14(10):506-10. Spanish.

PMID:
9424140
19.

Liposomal amphotericin B as first line and secondary prophylactic treatment for visceral leishmaniasis in a patient infected with HIV.

Borrelli P, Imperato A, Murdaca G, Scudeletti M.

Ann Ital Med Int. 2000 Apr-Jun;15(2):169-71.

PMID:
10920508
20.

Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.

Ritmeijer K, ter Horst R, Chane S, Aderie EM, Piening T, Collin SM, Davidson RN.

Clin Infect Dis. 2011 Dec;53(12):e152-8. doi: 10.1093/cid/cir674. Epub 2011 Oct 19.

PMID:
22016502

Supplemental Content

Support Center